Skip to main content
ImmuneCited

l-Cysteine and Vitamin D Co-Supplementation Alleviates Markers of Musculoskeletal Disorders in Vitamin D-Deficient High-Fat Diet-Fed Mice.

Rajesh Parsanathan, Arunkumar E Achari, Prasenjit Manna, Sushil K Jain
Other Nutrients 2020 12 atıf
PubMed DOI CC-BY PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'pmid\u003D33171932'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Çalışma Türü
animal study (controlled preclinical)
Süre
16 weeks
Müdahale
l-Cysteine and Vitamin D Co-Supplementation Alleviates Markers of Musculoskeletal Disorders in Vitamin D-Deficient High-Fat Diet-Fed Mice. not specified; LC alone, VD alone, or LC + VD for 8 weeks
Karşılaştırıcı
Placebo
Etki Yönü
Positive
Yanlılık Riski
Moderate

Abstract

Vitamin D (VD) deficiency is associated with musculoskeletal disorders. This study examines whether co-supplementation of l-cysteine (LC) and VD is better than monotherapy with LC or VD at alleviating musculoskeletal dyshomeostasis in the skeletal muscle of VD-deficient high-fat diet (HFD-VD-) fed mice. Mice were fed a healthy diet or an HFD; for VD-deficient animals, the mice were maintained on a HFD-VD-diet (16 weeks); after the first 8 weeks, the HFD-VD-diet-fed mice were supplemented for another 8 weeks with LC, VD-alone, or the same doses of LC + VD by oral gavage. Saline and olive oil served as controls. Myotubes were exposed with high-glucose, palmitate, Monocyte Chemoattractant Protein 1 (MCP-1), and Tumor Necrosis Factor (TNF), to mimic the in vivo microenvironment. In vitro deficiencies of glutathione and hydrogen sulfide were induced by knockdown of GCLC and CSE genes. Relative gene expression of biomarkers (myogenic: MyoD, Mef2c, Csrp3; muscle dystrophy: Atrogin1, Murf1, and Myostatin; bone modeling and remodeling: RANK, RANKL, OPG) were analyzed using qRT-PCR. Co-supplementatoin with LC + VD showed beneficial effects on gene expression of myogenic markers and OPG but reduced markers of dystrophy, RANK/RANKL in comparison to LC or VD alone-supplementation. In vitro myotubes treated with glutathione (GSH) precursors also showed a positive effect on OPG and the myogenesis genes, and inhibited RANK/RANKL and muscle-dystrophy markers. This study reveals that the co-supplementation of LC with VD significantly alleviates the markers of musculoskeletal disorders in the skeletal muscle better than monotherapy with LC or VD in HFD-VD-fed mice.

Full Text

PDF
Loading PDF...

Figures

Tables

Table 1

Atrogin1/Fbxo32skeletal muscle-specific F-box protein
CSE/CTHCystathionine Gamma-Lyase
GCLC/ γ-GCScGlutamate-Cysteine Ligase Catalytic Subunit
GSHGlutathione
H2SHydrogen sulfide
LCl-cysteine
HFD-VD-VD-deficient high-fat diet-fed
MCP-1Monocyte Chemoattractant Protein 1
TNFTumor Necrosis Factor
MuRF1/Trim63Muscle RING-finger protein-1
MstnMyostatin
MyoDMyoblast determination protein 1
Mef2cMyocyte enhancer factor 2C
Csrp3Cysteine and glycine-rich protein 3
Rank/Tnfrsf11aReceptor activator of nuclear factor-kB
RANKLReceptor activator of nuclear factor-kB ligand
OPGOsteoprotegerin
VDVitamin D

References

  1. Untitled
  2. Untitled
  3. Untitled
  4. Untitled
  5. Untitled
  6. Untitled
  7. Untitled
  8. Untitled
  9. Untitled
  10. Untitled
  11. Untitled
  12. Untitled
  13. Untitled
  14. Untitled
  15. Untitled
  16. Untitled
  17. Untitled
  18. Untitled
  19. Untitled
  20. Untitled
  21. Untitled
  22. Untitled
  23. Untitled
  24. Untitled
  25. Untitled
  26. Untitled
  27. Untitled
  28. Untitled
  29. Untitled
  30. Untitled
  31. Untitled
  32. Untitled
  33. Untitled
  34. Untitled
  35. Untitled
  36. Untitled
  37. Untitled
  38. Untitled
  39. Untitled
  40. Untitled
  41. Untitled
  42. Untitled
  43. Untitled
  44. Untitled
  45. Untitled
  46. Untitled
  47. Untitled
  48. Untitled
  49. Untitled
  50. Untitled
  51. Untitled
  52. Untitled
  53. Untitled
  54. Untitled

Used In Evidence Reviews

Similar Papers